TARA vs. ATYR, SIGA, TRML, PGEN, MREO, ORGO, PRTC, KMDA, ORKA, and ATAI
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Precigen (PGEN), Mereo BioPharma Group (MREO), Organogenesis (ORGO), PureTech Health (PRTC), Kamada (KMDA), Oruka Therapeutics (ORKA), and atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry.
Protara Therapeutics vs. Its Competitors
aTyr Pharma (NASDAQ:ATYR) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by insiders. Comparatively, 8.4% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Protara Therapeutics has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
aTyr Pharma presently has a consensus price target of $20.20, suggesting a potential upside of 284.47%. Protara Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 605.44%. Given Protara Therapeutics' higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than aTyr Pharma.
Protara Therapeutics' return on equity of -36.37% beat aTyr Pharma's return on equity.
In the previous week, Protara Therapeutics had 4 more articles in the media than aTyr Pharma. MarketBeat recorded 7 mentions for Protara Therapeutics and 3 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.66 beat Protara Therapeutics' score of 0.09 indicating that aTyr Pharma is being referred to more favorably in the media.
aTyr Pharma has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.
Summary
Protara Therapeutics beats aTyr Pharma on 8 of the 12 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TARA) was last updated on 7/3/2025 by MarketBeat.com Staff
Free TARA Stock Alerts